Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery

AIDS. 2009 Sep 10;23(14):1911-3. doi: 10.1097/QAD.0b013e32832f3c65.

Abstract

We reviewed the effect of adding maraviroc on CD4 cell counts in nine patients on antiretroviral therapy with full viral suppression but impaired CD4 cell recovery. There were no significant differences in changes in CD4 cell count, percentage of CD4 cells, or in the ratio of CD4/CD8 cells at 30 days and 25 weeks of maraviroc therapy. Plasma endotoxin levels measured in four patients before and during maraviroc treatment also showed no significant differences.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Antiretroviral Therapy, Highly Active / methods
  • CD4 Lymphocyte Count
  • Cyclohexanes / therapeutic use*
  • Drug Evaluation
  • Endotoxins / blood
  • HIV Fusion Inhibitors / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV-1 / isolation & purification*
  • Humans
  • Male
  • Maraviroc
  • Middle Aged
  • RNA, Viral / blood
  • Retrospective Studies
  • Treatment Outcome
  • Triazoles / therapeutic use*

Substances

  • Cyclohexanes
  • Endotoxins
  • HIV Fusion Inhibitors
  • RNA, Viral
  • Triazoles
  • Maraviroc